These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33566254)

  • 1. Dissociated response and clinical benefit in patients treated with nivolumab monotherapy.
    Sato Y; Morimoto T; Hara S; Nagata K; Hosoya K; Nakagawa A; Tachikawa R; Tomii K
    Invest New Drugs; 2021 Aug; 39(4):1170-1178. PubMed ID: 33566254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
    Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Seike M; Gemma A; Nishio M
    BMC Cancer; 2020 Mar; 20(1):207. PubMed ID: 32164651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
    Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
    Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
    J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab.
    Kawachi H; Fujimoto D; Morimoto T; Hosoya K; Sato Y; Kogo M; Nagata K; Nakagawa A; Tachikawa R; Tomii K
    Invest New Drugs; 2019 Dec; 37(6):1257-1265. PubMed ID: 30937690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
    Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.
    Zhou H; Sun Y; Xiu W; Han J; Zhong L; Suo J; Wei H; Wang Y; Zhu J
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2979-2988. PubMed ID: 32518972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
    Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
    JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.
    Kataoka Y; Hirano K; Narabayashi T; Hara S; Fujimoto D; Tanaka T; Ebi N; Tomii K; Yoshioka H
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):333-337. PubMed ID: 29230503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do systemic treatments delivered after Nivolumab result in better outcomes? A bicentric case-control study.
    Darrason M; Chatelain E; Ranchon F; Gervaise C; Duruisseaux M; Couraud S
    Respir Med Res; 2020 Mar; 77():100-105. PubMed ID: 32512522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociated response to PD-1 inhibitors combined with radiotherapy in patients with advanced metastatic solid tumors: a single-center experience.
    Yu Q; Zhang H; Song Y; Chen C; Chen J; Shen J
    World J Surg Oncol; 2023 Jul; 21(1):228. PubMed ID: 37501167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
    Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
    JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
    Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
    Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
    Waterhouse DM; Garon EB; Chandler J; McCleod M; Hussein M; Jotte R; Horn L; Daniel DB; Keogh G; Creelan B; Einhorn LH; Baker J; Kasbari S; Nikolinakos P; Babu S; Couture F; Leighl NB; Reynolds C; Blumenschein G; Gunuganti V; Li A; Aanur N; Spigel DR
    J Clin Oncol; 2020 Nov; 38(33):3863-3873. PubMed ID: 32910710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
    J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting.
    Takada K; Shimokawa M; Takamori S; Shimamatsu S; Hirai F; Tagawa T; Okamoto T; Hamatake M; Tsuchiya-Kawano Y; Otsubo K; Inoue K; Yoneshima Y; Tanaka K; Okamoto I; Nakanishi Y; Mori M
    Int J Cancer; 2021 Jul; 149(2):473-482. PubMed ID: 33720422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.